Last reviewed · How we verify
Pazopanib as add-on to vinflunine
Pazopanib as add-on to vinflunine is a Small molecule drug developed by Prof. Dr. Thomas Otto. It is currently in Phase 1 development. Also known as: Pazopanib is marketed as Votrient., Vinflunine is marketed as Javlor..
At a glance
| Generic name | Pazopanib as add-on to vinflunine |
|---|---|
| Also known as | Pazopanib is marketed as Votrient., Vinflunine is marketed as Javlor. |
| Sponsor | Prof. Dr. Thomas Otto |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Pazopanib and Vinflunine in Urothelial Cancer of the Bladder (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pazopanib as add-on to vinflunine CI brief — competitive landscape report
- Pazopanib as add-on to vinflunine updates RSS · CI watch RSS
- Prof. Dr. Thomas Otto portfolio CI
Frequently asked questions about Pazopanib as add-on to vinflunine
What is Pazopanib as add-on to vinflunine?
Pazopanib as add-on to vinflunine is a Small molecule drug developed by Prof. Dr. Thomas Otto.
Who makes Pazopanib as add-on to vinflunine?
Pazopanib as add-on to vinflunine is developed by Prof. Dr. Thomas Otto (see full Prof. Dr. Thomas Otto pipeline at /company/prof-dr-thomas-otto).
Is Pazopanib as add-on to vinflunine also known as anything else?
Pazopanib as add-on to vinflunine is also known as Pazopanib is marketed as Votrient., Vinflunine is marketed as Javlor..
What development phase is Pazopanib as add-on to vinflunine in?
Pazopanib as add-on to vinflunine is in Phase 1.
Related
- Manufacturer: Prof. Dr. Thomas Otto — full pipeline
- Also known as: Pazopanib is marketed as Votrient., Vinflunine is marketed as Javlor.
- Compare: Pazopanib as add-on to vinflunine vs similar drugs
- Pricing: Pazopanib as add-on to vinflunine cost, discount & access